News and Announcements
Folkestone Education Trust Increases Debt Facilities by $50 Million
- Published July 03, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Effective from 29 June 2017, the Folkestone Education Trust (“FET”) increased the facility limits of its bilateral banking facilities by $50 million to $317 million.
KEY TAKEAWAYS:
- The facilities are currently drawn to $245 million, resulting in $72 million remaining undrawn and available to fund FET’s development pipeline.
- The increase in facilities was provided equally by FET’s current lenders, Australia and New Zealand Banking Group Limited and Hongkong and Shanghai Banking Corporation Limited.
- Increased the maturity of debt facilities totalling $133.5 million by one year, resulting in a weighted average debt maturity of 3.5 years as at 30 June 2017.
As part of FET’s interest rate management policy, additional hedging positions have been taken out to extend the hedging profile through to June 2022 and to supplement FET’s existing positions between FY18 and FY21. For FY18, $172 million (70%) of the drawn debt is now hedged at an average rate of 2.8% per annum (excluding margin and line fee). The average hedging position over a five year period to June 2022 is 55% hedged at an average rate of 2.95% per annum on the same basis.
Based on the revised debt and hedging arrangements, it is forecast that FET’s cost of debt will be marginally reduced to approximately 4.2% per annum as at 30 June 2017.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
